NEW: Updated NCCN Multiple Myeloma Guidelines Strengthen MRD Testing Recommendations and Specifically Reference clonoSEQ
FDA-cleared and covered by Medicare, clonoSEQ meets the requirements of the updated guidelines and provides highly sensitive MRD testing across the treatment continuum in multiple myeloma. For more info about this exciting update, read our press release here.
Resources
Materials for you and your practice
Download helpful materials to keep information nearby about the basics of clonoSEQ, specimen requirements, and more.
clonoSEQ HCP Brochure
Everything you need to know about clonoSEQ, including how it benefits patients, in one resource.
clonoSEQ Portal Walkthrough
Step-by-step guidance on how to order clonoSEQ through the Diagnostic Portal.
clonoSEQ Ordering Quick Facts Sheet
Learn how clonoSEQ works, how to place an order, and about general specimen requirements at a glance.
How to place clonoSEQ orders through Epic Integration
Step by step guidance on how to order clonoSEQ through Epic
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.